231 related articles for article (PubMed ID: 11218878)
1. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
Liu C; Duan Y; Wu X
Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
[TBL] [Abstract][Full Text] [Related]
2. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
3. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
[TBL] [Abstract][Full Text] [Related]
4. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
5. Remission of Graves' hyperthyroidism treated with methimazole.
Bolaños F; González-Ortiz M; Durón H; Sánchez C
Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
[TBL] [Abstract][Full Text] [Related]
6. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
[TBL] [Abstract][Full Text] [Related]
7. Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal.
Orunesu E; Bagnasco M; Salmaso C; Altrinetti V; Bernasconi D; Del Monte P; Pesce G; Marugo M; Mela GS
Eur J Clin Invest; 2004 Mar; 34(3):210-7. PubMed ID: 15025680
[TBL] [Abstract][Full Text] [Related]
8. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
9. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
[TBL] [Abstract][Full Text] [Related]
10. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
[TBL] [Abstract][Full Text] [Related]
12. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
13. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
Gauna AT; Guillén CE; Sartorio GC; Soto RJ
Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
Massart C; Gibassier J; d'Herbomez M
Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
[TBL] [Abstract][Full Text] [Related]
15. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
16. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
Wu G; Jie Y; Situ Y
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
[TBL] [Abstract][Full Text] [Related]
17. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N
Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
Reinwein D; Benker G; Lazarus JH; Alexander WD
J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
[TBL] [Abstract][Full Text] [Related]
19. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
[TBL] [Abstract][Full Text] [Related]
20. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
Li J; Gao H; Xu L
Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
